COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,235 Articles (22,733 medRxiv, 8,502 bioRxiv)

Most recent first Previous |  Page 1798: Articles 17971-17980  | Next

Recent SARS-CoV-2 seroconversion in a national, community-based prospective cohort of U.S. adults
Nash, D., Rane, M., Chang, M., Kulkarni, S., Zimba, R., You, W., Berry, A., Mirzayi, C., Kochhar, S., Maroko, A. R., Robertson, M., Westmoreland, D., Parcesepe, A., Waldron, L., Grov, C., for the CHASING COVID Cohort Study Team
10.1101/2021.02.12.21251659 — Posted: 2021-02-16
Biological attributes of age and gender variations in Indian COVID-19 cases: A retrospective data analysis
Kushwaha, S., Khanna, P., Rajagopal, V., Kiran, T.
10.1101/2021.02.13.21251681 — Posted: 2021-02-16
Impact of January 2021 social distancing measures on SARS-CoV-2 B.1.1.7 circulation in France
Di Domenico, L., Pullano, G., Sabbatini, C. E., Levy-Bruhl, D., Colizza, V.
10.1101/2021.02.14.21251708 — Posted: 2021-02-16
Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study
Sheehan, M. M., Reddy, A. J., Rothberg, M. B.
10.1101/2021.02.14.21251715 — Posted: 2021-02-16
Ruling out SARS-CoV-2 infection using exhaled breath analysis by electronic nose in a public health setting
de Vries, R., Vigeveno, R. M., Mulder, S., Farzan, N., Vintges, D. R., Goeman, J. J., Bruisten, S., van der Corput, B., Geelhoed, J. J. M., Visser, L. G., van der Lubben, M., Sterk, P. J., in 't Veen, J. C. C. M., Groeneveld, G. H.
10.1101/2021.02.14.21251712 — Posted: 2021-02-16
A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples
Sancilio, A., D'Aquila, R., MCNALLY, E., Velez, M., Ison, M., Demonbreun, A. R., McDade, T. W.
10.1101/2021.02.14.21251709 — Posted: 2021-02-16
Comparison of SARS-CoV-2 viral load in saliva samples in symptomatic and asymptomatic cases
Bhatta, A., Henkhaus, R., Fehling, H. L.
10.1101/2021.02.12.21251229 — Posted: 2021-02-16
Treatment of irritant contact dermatitis in healthcare settings during the COVID19 pandemic: The emollient Dermol 500 exhibits virucidal activity against influenza A virus and SARS-CoV-2.
Styles, C. T., Vanden Oever, M., Brown, J., Rai, S., Walsh, S., Ryan, F. M., Barclay, W. S., Edgar, R. S.
10.1101/2021.02.12.21251419 — Posted: 2021-02-16
Confirmation of an Inverse Relationship between Bioaerosol Count and Influenza-like Illnesses, Including COVID-19. On the Contribution of Mold Spores
Shah, R. B., Shah, R. D., Retzinger, D. G., Retzinger, A. C., Retzinger, D. A., Retzinger, G. S.
10.1101/2021.02.07.21251322 — Posted: 2021-02-16
SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1
Pagano, S., Yerly, S., Meyer, B., Juillard, C., Suh, N., LeTerrier, C., Daguer, J.-P., Farrera Soler, L., Barluenga, S., Piumatti, G., Hartley, O., Lemaitre, B., Eberhardt, C. S., Siegrist, C.-A., Eckerle, I., Stringhini, S., Guessous, I., Kaiser, L., Pugin, J., Winssinger, N., Vuilleumier, N.
10.1101/2021.02.12.21251298 — Posted: 2021-02-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).